Who are Elrexfio's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TECVAYLI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/elranatamab-bcmm.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Elrexfio — Competitive Intelligence Brief

Elrexfio (elranatamab-bcmm) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Tumor necrosis factor receptor superfamily member 17 Oncology Bispecific antibody Live · refreshed every 30 min

Target snapshot

Elrexfio (elranatamab-bcmm) — Pfizer. Elrexfio works by binding to tumor necrosis factor receptor superfamily member 17, a protein involved in the growth and survival of cancer cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Elrexfio TARGET	elranatamab-bcmm	Pfizer	marketed		Tumor necrosis factor receptor superfamily member 17	2023-01-01
TECVAYLI	TECLISTAMAB-CQYV	JANSSEN BIOTECH	marketed		Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3

Recent regulatory actions (last 90 days)

2026-02-19 — Elrexfio · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Elrexfio — Competitive Intelligence Brief. https://druglandscape.com/ci/elranatamab-bcmm. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab